We are advancing a pipeline of AlloCAR TTM candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Our AlloCAR T portfolio includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to clinical candidates ALLO-501 and UCART19, currently in Phase 1 development for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) and relapsed/refractory acute lymphoblastic leukemia (ALL), respectively.
Servier is the sponsor of the UCART19 program, which is currently in Phase 1 for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Allogene has exclusive rights to UCART19 in the U.S. while Servier holds ex-US commercial rights. Learn more about the PALL and CALM studies.
Allogene initiated its Phase 1/2 ALPHA study of ALLO-501 in the first half of 2019 to assess safety and tolerability of ALLO-501 and ALLO-647, our proprietary anti-CD52 monoclonal antibody, in patients with the most common non-Hodgkin lymphoma (NHL) subtypes of relapsed/refractory diffuse large B-cell lymphoma (DLBCL or follicular lymphoma (FL). Allogene is the sponsor of the ALLO-501 program and has exclusive rights in the U.S., while Servier holds ex-U.S. commercial rights. Learn more about NHL.
Pre-Clinical program targeting FLT3 in acute myeloid leukemia.
Pre-Clinical program targeting CD70 in other hematological malignancies
Pre-Clinical program targeting DLL3 in small cell lung cancer (SCLC).
ALLO-647 is Allogene’s proprietary anti-CD52 monoclonal antibody administered as part of a lymphodepletion regimen in Allogene’s clinical trials. ALLO-647 is intended to enable expansion and persistence of allogeneic CAR T product candidates.
1Phase 3 may not be required if Phase 2 is registrational